Campylobacter Spp. Epidemiology and Antimicrobial Susceptibility in a Developing Country, Burkina Faso (West Africa)

L Sangaré, AK Nikiéma, S Zimmermann, I Sanou, M Congo-Ouédraogo, A Diabaté, S Diandé, PI Guissou

 

Abstract

Data on campylobacteriosis are almost nonexistent in Burkina Faso. In this study conducted from 2006 to 2008 in Ouagadougou, stool specimens and sociodemographic data were collected from 1 246 patients attending the university teaching hospital for enteritis. Stool samples were analyzed for the presence of Campylobacter by the direct culture method on selective mCCDA agar followed by antibiotic susceptibility testing on the isolated strains. The isolation rate of Campylobacter was 2.3%,comprising of the following species C. jejuni (51.8%), C. coli(13.8%), and C. upsaliensis (3.5%). However, 30.9% of the isolates were unidentified. No resistant strain was found to gentamicin. The resistance to amoxicillin+clavulanic acid (3.4%) was lower than those (10.3-34.5%) to the other antibiotics: erythromycin (10.3%), tetracycline (10.3%), ciprofloxacin (13.8%), amoxicillin (24.1%) and ceftriaxone (34.5%), nalidixic acid (34.5%). Significant associations were found betweenCampylobacter enteritis and contact with animals (P=0.03), and HIV infection (P<0.0001), in contrast to other sociodemographic and seasonal factors. From the data obtained Amoxicillin+clavulanic acid appear to be the first choice for treatment. The implementation of a national program may be helpful in controlling the spread of the disease and the increase of resistance to antibiotics.

Keywords: Campylobacter, epidemiology, HIV, drug resistance, Burkina Faso

Download full journal in PDF below

Campylobacter Spp. Epidemiology and Antimicrobial Susceptibility in a Developing Country, Burkina Faso (West Africa)

HIV infection and mycobacterium tuberculosis drug-resistance among tuberculosis patients in Burkina Faso, West Africa

L Sangaré, S Diandé, G Ouédraogo, A.S Traoré

 

Abstract

The aim of this study was to compare the drug-resistance patterns of Mycobacterium tuberculosis strains among pulmonary tuberculosis patients, according to their HIV serostatus, in Burkina Faso. Tuberculosis (TB) patients were classified in new and previously treated cases by using a structured questionnaire. Susceptibility testing to isoniazid, streptomycin, rifampicin and ethambutol was done by the proportion method. Association between HIV-serostatus and drug-resistant TB was assessed with χ2 tests, and the statistical significance was set to P<0.05. Of 316 (249 new, 67 previously treated) patients included in the study, 68.7% were males and 28.8% were HIV-positive; females (36.4%) were more infected than males
(25.3%), (P=0.04). The average age of the patients was 37.24±12.76 years [11-75years]. Most of the patients infected with HIV were aged from 15 to 44 years and were females, (P=0.01). In the new cases of TB, the difference between HIV-positive and HIV-negative patients was not statistically significant neither for the MDR-TB (P=0.40), nor for the resistant-TB to any drug (P=0.26). However, the difference was significant for the resistance to isoniazid and streptomycin alone (P=0.04). Among the previously treated patients, although there was more MDR-TB and more resistance to any drug in HIV-negative patients than among HIV-positive patients, these differences also were not statistically significant (P=0.54 and P=0.63, respectively). This study found no significant difference between TB/HIV-negative and TB/HIV-positive patients according to the resistance patterns to anti-TB medications, excepted the resistance to isoniazid in new cases and to isoniazid and streptomycin in all patients took globally. These results encourage the collaboration between the programs against TB and HIV to prevent rapid diffusion of drug-resistant TB and high mortality in patients living with HIV/AIDS as recommended by the World Health Organization.

Keywords: Tuberculosis, HIV, Drug resistance, Burkina Faso

Download full journal in PDF below

HIV infection and mycobacterium tuberculosis drug-resistance among tuberculosis patients in Burkina Faso, West Africa